.Alnylam is suspending additionally growth of a clinical-stage RNAi therapeutic created to treat Sty...
.Takeda has quit (PDF) a period 2 trial of danavorexton because of sluggish registration, denoting a...
.Compass Pathways' trip to period 3 psychedelic anxiety records is taking much longer than expected....
.After antibody-drug conjugate (ADC) expert Seagen was sold to Pfizer last year for a massive $43 bi...
.On the heels of a stage 3 gain that neglected to blow away clients, Ironwood Pharmaceuticals is act...
.Don't quit Monte Rosa Rehabs now. The Boston-based biotech is actually having a ball after authoriz...
.Invite to today's Chutes & Ladders, our summary of notable leadership hirings, firings as well a...
.Celebrating his company's upsized initial public offering (IPO), Septerna CEO Jeffrey Finer called ...
.AbbVie has returned to the source of its own antipsychotic goliath Vraylar seeking yet another bloc...
.GenSight Biologics is weeks far from losing cash. Once again. The biotech just has adequate cash mo...